Promise of vitamin D analogues in the treatment of hyperproliferative conditions

Molecular Cancer Therapeutics

Volumn 5, Issue 4, 2006, Pages 797-808

  Masuda, Sonoko ^a   Jones, Glenville ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CARBOPLATIN; CISPLATIN DERIVATIVE; CYTOCHROME P450 INHIBITOR; CYTOTOXIC AGENT; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; GEFITINIB; GEMCITABINE; KETOCONAZOLE; MITOXANTRONE; PACLITAXEL; PACLITAXEL DERIVATIVE; PREDNISONE; SEOCALCITOL; VITAMIN D; ZOLEDRONIC ACID;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CANCER MODEL; CANCER THERAPY; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; DRUG BIOAVAILABILITY; DRUG MEGADOSE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HYPERCALCEMIA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCITRIOL; CELL CYCLE; CELL DIVISION; HUMANS; NEOPLASMS; TRANSCRIPTION, GENETIC; VITAMIN D;

EID: 33646564673     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0539     Document Type: Review

References (110)

1. Holick MF. Chapter 3: Photobiology of vitamin D. In: Feldman D, Pike JW, Glorieux FH, editors. Vitamin D. 2nd ed. New York: Elsevier Academic Press; 2005. p. 37-46.
2. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998;78:1193-231.
3. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004;29:664-73.
4. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A 2004;101:7711-5.
5. Hollis BW. Chapter 58: Detection of vitamin D and its major metabolites. In: Feldman D, Pike JW, Glorieux FH, editors. Vitamin D. 2nd ed. New York: Elsevier Academic Press; 2005. p. 931-50.
6. Safadi FF, Thornton P, Magiera H, et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest 1999;103:239-51.
7. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80:1678-88S.
8. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005;16:713-6.
9. St-Arnaud R, Messerlian S, Moir JM, Omdahl JL, Glorieux FH. The 25-hydroxyvitamin D-1α-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J Bone Miner Res 1997;12:1552-9.
10. 3 whose mutation causes vitamin D-dependent rickets type 1. J Biol Chem 2005;280:30511-6.
11. Panda DK, Miao D, Bolivar I, et al. Inactivation of the 25-hydroxyvitamin D 1α-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004;279:16754-66.
12. 3-1α-hydroxylase and 24-hydroxylase gene transcription in opossum kidney cells. Arch Biochem Biophys 2003;409:298-304.
13. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 2003;285:E1-9.
14. 3 by pulmonary alveolar macrophages from patients with sarcoidosis. Ann N Y Acad Sci 1986;465:587-94.
15. Adams JS, Ren SY. Autoregulation of 1,25-dihydroxyvitamin D synthesis in macrophage mitochondria by nitric oxide. Endocrinology 1996;137:4514-7.
16. Schilling T, Pecherstorfer M, Blind E, Leidig G, Ziegler R, Raue F. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. J Clin Endocrinol Metab 1993;76:801-3.
17. Hewison M, Adams JS. Chapter 79: Extra-renal 1α-hydroxylase activity and human disease. In: Feldman D, Pike JW, Glorieux FH, editors. Vitamin D. 2nd ed. New York: Elsevier Academic Press; 2005. p. 1379-402.
18. Schwartz GG. Vitamin D and the epidemiology of prostate cancer. Semin Dial 2005;18:276-89.
19. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005;135:317-22.
20. Jones G. The clinical utility of blood 25-OH-D measurement - new uses for an old tool? DEQAS Newsletter, 2005 Oct.
21. Whitfield GK, Jurutka PW, Haussler C, et al. Chapter 13: Nuclear receptor: structure-function, molecular control of gene transcription and novel bioactions. In: Feldman D, Pike JW, Glorieux FH, editors. Vitamin D. 2nd ed. New York: Elsevier Academic Press; 2005. p. 219-62.
22. 3-regulated gene expression by microarray analysis. J Steroid Biochem Mol Biol 2004;89-90: 239-44.
23. Freedman LP, Reszka AA. Chapter 14: Vitamin D receptor cofactors: function, regulations and sensitivity In: Feldman D, Pike JW, Glorieux FH, editors. Vitamin D. 2nd ed. New York: Elsevier Academic Press; 2005. p. 263-77.
24. Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 2000;5:173-9.
25. Malloy PJ, Pike JW, Feldman D. Chapter 72: Hereditary 1,25-dihydroxyvitamin D resistant rickets. In: Feldman D, Pike JW, Glorieux FH, editors. Vitamin D. 2nd ed. New York: Elsevier Academic Press; 2005. p. 1207-30.
26. 3 effective on intestine. J Biol Chem 1973;248:6691-6.
27. 3 24-hydroxylase. FEBS Lett 1991;278:195-8.
28. 3 to calcitroic acid: evidence for a pathway in kidney and bone involving 24-oxidation. Biochem J 1989;262:173-80.
29. 3 in target cells. J Nutr Sci Vitaminol (Tokyo) 1992;Special Issue. p. 75-8.
30. 3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (CYP24A1) null mouse. Endocrinology 2005;146:825-34.
31. Albertson DG, Ylstral B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identified CYP24 as a candidate oncogene. Nat Genet 2000;25:144-6.
32. Schuster I, Egger H, Astecker N, Herzig G, Schussler M, Vorisek G. Selective inhibitors of CYP24: mechanistic tools to explore vitamin D metabolism in human keratinocytes. Steroids 2001;66:451-62.
33. 3. J Steroid Biochem Mol Biol 2004;89-90:5-12.
34. Farhan H, Cross HS. Transcriptional inhibition of CYP24 by genistein. Ann N Y Acad Sci 2002;973:459-62.
35. Masuda S, Jones G. Vitamin D analogs: drug design based upon proteins involved in vitamin D signal transduction. Curr Drug Targets Immune Endocr Metabol Disord 2003;3:43-67.
36. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201.
37. 3. Proc Natl Acad Sci U S A 1981;78:4990-4.
38. 3 leads to the induced differentiation of the myelo-monocytic cell line U937. Genes Dev 1996;10:142-53.
39. 3 in HL60 cells. Cancer Res 1996;56:264-7.
40. 1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 2003;278:46862-8.
41. Lin R, Wang TT, Miller WH, Jr., White JH. Inhibition of F-Box protein p45(SKP2) expression and stabilization of cyclin-dependent kinase inhibitor p27(KIP1) in vitamin D analog-treated cancer cells. Endocrinology 2003;144:749-53.
42. Li P, Li C, Zhao X, Zhang X, Nicosia SV, Bai W. p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J Biol Chem 2004;279:25260-7.
43. 3 induction in myeloid leukemic cells. Mol Cell Biol 1998;18:1911-8.
44. Bettoun DJ, Buck DW II, Lu J, Khalifa B, Chin WW, Nagpal S. A vitamin D receptor-Ser/Thr phosphatase-p70 S6 kinase complex and modulation of its enzymatic activities by the ligand. J Biol Chem 2002;277:24847-50.
45. 3 analog-induced growth inhibition in breast cells. J Cell Physiol 2001;188:383-93.
46. Colston KW, Perks CM, Xie SP, Holly JM. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 1998;20:157-62.
47. Rozen F, Yang XF, Huynh H, Pollak M. Anti-proliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation. J Natl Cancer Inst 1997;89:652-6.
48. 3 and TGF-β1 on the production of insulin-like growth factor binding protein 3 in human bone marrow stromal cell cultures. APMIS 2002;110:410-4.
49. Peehl DM, Krishnan AV, Feldman D. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 2003;133:2461-9S.
50. 3-induced apoptosis of retinoblastoma cells is associated with reciprocal changes of Bcl-2 and bax. Exp Eye Res 2003;77:1-9.
51. Mathiasen IS, Sergeev IN, Bastholm L, Elling F, Norman AW, Jaattela M. Calcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells. J Biol Chem 2002;277:30738-45.
52. 3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clin Cancer Res 2003;9:2350-6.
53. Weitsman GE, Ravid A, Liberman UA, Koren R. Vitamin D enhances caspase-dependent and -independent TNFα-induced breast cancer cell death: the role of reactive oxygen species and mitochondria. Int J Cancer 2003;106:178-86.
54. Kim RH, Peters M, Jang Y, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 2005;7:263-73.
55. 3-induced monocytic differentiation of HL60 cells. Cancer Res 2004;64:370-7.
56. Lamb J, Ramaswamy S, Ford HL, et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 2003;114:323-34.
57. Studzinski GP, Wang X, Ji Y, et al. The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway. J Steroid Biochem Mol Biol 2005;97:47-55.
58. 3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a] anthracene. Anticancer Drugs 1991;2:475-80.
59. 3 inhibits angiogenesis in vitro and in vivo. Circ Res 2000;87:214-20.
60. Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP. 1α,25- Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 1997;6:727-32.
61. 3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 2005;26:1044-54.
62. 3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ 2000;11:221-9.
63. 3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol 2000;164:133-43.
64. 3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β-catenin signaling. J Cell Biol 2001;154:369-87.
65. 3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett 1998;426:225-8.
66. 3 and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002;143:2508-14.
67. Matsumoto H, Iino Y, Koibuchi Y, et al. Antitumor effect of 22-oxacalcitriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice. Oncol Rep 1999;6:349-52.
68. Palmer HG, Larriba MJ, Garcia JM, et al. The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nat Med 2004;10:917-9.
69. 3 receptor signalling in prostate cancer cells. Oncogene 2004;23:6712-25.
70. 3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors. J Steroid Biochem Mol Biol 2004;89-90:245-9.
71. Colston KW, Pirianov G, Bramm E, Hamberg KJ, Binderup L. Effects of seocalcitol (EB1089) on nitrosomethyl urea-induced rat mammary tumors. Breast Cancer Res Treat 2003;80:303-11.
72. El Abdaimi K, Dion N, Papavasiliou V, et al. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res 2000;60:4412-8.
73. Abe-Hashimoto J, Kikuchi T, Matsumoto T, Nishii Y, Ogata E, Ikeda K. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res 1993;53:2534-7.
74. 3 (OCT) as a single agent or combined therapy with aromatase inhibitor (CGS 16949A) on 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors. Int J Oncol 1996;9:79-82.
75. Haq M, Kremer R, Goltzman D, Rabbani SA. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J Clin Invest 1993;91:2416-22.
76. Endo K, Ichikawa F, Uchiyama Y, et al. Evidence for the uptake of a vitamin D analogue (OCT) by a human carcinoma and its effect of suppressing the transcription of parathyroid hormone-related peptide gene in vivo. J Biol Chem 1994;269:32693-9.
77. 3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res 2000;60:2673-9.
78. Anzano MA, Smith JM, Uskokovic MR, et al. 1α,25-Dihydroxy-16-ene- 23-yne-26,27-hexafluoro-cholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res 1994;54:1653-6.
79. 5. J Steroid Biochem Mol Biol 2005;97:129-36.
80. 3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res Treat 1999;53:113-20.
81. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res 2000;60:779-82.
82. Lokeshwar BL, Schwartz GG, Selzer MG, et al. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 1999;8:241-8.
83. 3. J Steroid Biochem Mol Biol 2005;97:203-11.
84. 3 and prostate cancer cell proliferation in vivo. Urology 1995;46:365-9.
85. Lucia MS, Anzano MA, Slayter MV, et al. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res 1995;55:5621-7.
86. Polek TC, Murthy S, Blutt SE, et al. Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. Prostate 2001;49:224-33.
87. 3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model. Dis Colon Rectum 1997;40:317-21.
88. 3 synthetic analogs inhibit spontaneous metastases in a 1,2-dimethylhydrazine-induced colon carcinogenesis model. Int J Oncol 2000;16:1249-54.
89. 3, inhibits azoxymethane-induced colonic tumorigenesis. Cancer Res 1995;55:3050-4.
90. 3 and its synthetic analogue, 1α,25-dihydroxy-16-ene-23yne-26,27-hexafluoro-19-nor- cholecalciferol (Ro 25-6760), on a human colon cancer xenograft. Clin Cancer Res 1998;4:2869-76.
91. 3. Carcinogenesis 1995;16:2091-7.
92. Spina C, Tangpricha V, Yao M, et al. Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogs. J Steroid Biochem Mol Biol 2005;97:111-20.
93. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 1999;5:1339-45.
94. Beer TM, Munar M, Henner WD. A phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 2001;91:2431-9.
95. Muindi JR, Peng Y, Potter DM, et al. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 2002;72:648-59.
96. Slatopolsky E, Weeerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984;74:2136-43.
97. 3 for liver cancers. J Gastroenterol Hepatol 2001;16:333-7.
98. Beer TM, Myrthue A, Garzotto M, et al. Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2004;13:2225-32.
99. Beer TM. Development of weekly high-dose calcitriol based therapy for prostate cancer. Urol Oncol 2003;21:399-405.
100. Beer TM, Garzotto M, Katovic NM. High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. Am J Clin Oncol 2004;27:535-41.
101. Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. J Urol 2005;174:888-92.
102. Gulliford T, English J, Colston KW, Menday P, Moller S, Coombes RC. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer 1998;78:6-13.
103. Dalhoff K, Dancey J, Astrup L, et al. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 2003;89:252-7.
104. Evans TR, Colston KW, Lofts FJ, et al. A phase II trial of the vitamin D analogue seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 2002;86:680-5.
105. 2 in the treatment of advanced androgen-independent prostate cancer. Clin Cancer Res 2003;9:4077-83.
106. 2 in patients with hormone refractory prostate cancer. Clin Cancer Res 2002;8:2820-7.
107. 2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res 2005;11:8680-5.
108. 3 analogue, in a phase I study of patients with advanced malignancies. Invest New Drugs 2003;21:445-52.
109. Beer TM, Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Mol Cancer Ther 2004;3:373-81.
110. Trump DL, Hershberger PA, Bernardi RJ, et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 2004;89-90:519-26.